

Keensight hires David Piccoli as Senior Analyst

Keensight Capital, a leading player in European Growth Private Equity¹, today announces that David Piccoli is joining its team as Senior Analyst.



David Piccoli benefits from over 3 years of experience in private-equity investing within Europe, and has developed a particularly strong expertise in the healthcare sector.

David begun his career in 2013 as an analyst within the Healthcare team of the 3i group. He actively helped this team to become independent from the 3i group, a process which established a new entity, the investment fund ArchiMed. As a founding member of the ArchiMed team, he worked for 2 years as Senior Analyst, and had specific responsibilities for covering the Italian market within his role.

David, who is 27, is a graduate of ESCP Europe and has a Master's degree in finance from London City University. Of Italian origin, David has worked in London, Paris and Milan, and speaks Italian, French, English and Spanish.

- - -

About Keensight Capital

Keensight Capital is a leading European Growth Private Equity firm managing funds backed by European institutional investors. Keensight Capital targets first-class international projects to finance organic growth or build-up strategies, or to cash out existing shareholders. Specific sectors of interest include Media/Internet, Information Technology, Healthcare, and Services. In each of these sectors, our team provides insights and expertise through its entrepreneurial and operational background and its access to a worldwide network built over the past 15 years.

www.keensightcapital.com

Press contacts

Citigate Dewe Rogerson

Aliénor Miens - alienor.miens@citigate.fr - +33 (0)1 53 32 84 77

Dominic Riding - dominic.riding@citigate.fr - +33 (0)1 53 32 84 74

¹ *Growth Private Equity*: investment in profitable, private companies experiencing strong growth, in minority or majority positions, with or without leverage, using a flexible approach adapted to the needs of individual entrepreneurs, in order to finance organic growth projects, acquisition strategies or provide historic shareholders with liquidity.